United States Market for Ankylosing Spondylitis Pharmacotherapy
United States Market for Ankylosing Spondylitis Pharmacotherapy
Low Disease Awareness Results in Substantial Untapped Market
RELEASE DATE
05-Jul-2012
05-Jul-2012
REGION
North America
North America
Research Code: NB3B-01-00-00-00
SKU: HC02233-NA-MR_07975
$4,950.00
In stock
SKU
HC02233-NA-MR_07975
Description
This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.
Table of Contents
Analysis of the Ankylosing Spondylitis Pharmacotherapeutics Market in the United States
- Executive Summary and Market Overview
Analysis of the Total Ankylosing Spondylitis Pharmacotherapeutics Market
- Drivers and Restraints
- Forecasts and Trends
- Demand Analysis
- Market Share and Competitive Analysis
Analysis of the TNF Inhibitor Segment
- Segment Breakdown and Market Engineering Measurements
- Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
- Market Share Analysis
Analysis of the Non-TNF Biologics Segment
- Segment Breakdown
- Patient Forecast
- Pricing Trends and Forecast
- Revenue Forecast
The Last Word
- Summary and Conclusions
Popular Topics
This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics.
No Index | Yes |
---|---|
Podcast | No |
Author | Deborah Toscano |
Industries | Healthcare |
WIP Number | NB3B-01-00-00-00 |
Is Prebook | No |